Wetsel R A, Jones M A, Kolb W P
J Immunol Methods. 1980;35(3-4):319-35. doi: 10.1016/0022-1759(80)90258-6.
The fifth component of complement (C5) has been isolated from human serum in fully hemolytically active form by immunoadsorbent and anion exchange column chromatography. The immunoadsorbent column was prepared by the covalent coupling of the purified IgG fraction obtained from monospecific goat anti-human C5 antiserum to CNBr activated Sepharose 4B. Establishment of appropriate conditions for the dissociation and elution of functionally active C5 from the immunoadsorbent column was of central importance in the development of this purification procedure. The C5 preparations exhibited final yields of 20--50% with 570--710-fold purification factors based on recovery of specific hemolytic activity. These preparations were free of contaminating serum proteins as judged by SDS-polyacrylamide slab gel electrophoretic and immunochemical criteria. A C5-depleted reagent (C5D) was generated from the non-adsorbed protein containing fractions obtained subsequent to the passage of freshly drawn NHS plus 10 mM EDTA through the monospecific anti-C5 Sepharose 4B column. Upon reconstitution of C5D with Ca2+, Mg2+, and C1q, this reagent was utilized for the detection and quantitation of C5 hemolytic activity. The purified C5 preparations contained 1.5--2.5 x 10(12) effective molecules/mg protein and NHS expressed 0.5--2.0 x 10(11) effective molecules/ml.
补体的第五成分(C5)已通过免疫吸附和阴离子交换柱色谱法从人血清中以完全溶血活性形式分离出来。免疫吸附柱是通过将从单特异性山羊抗人C5抗血清中获得的纯化IgG组分共价偶联到溴化氰活化的琼脂糖4B上制备的。建立从免疫吸附柱上解离和洗脱功能活性C5的合适条件是该纯化方法开发的核心要点。基于特异性溶血活性的回收率,C5制剂的最终产率为20%-50%,纯化倍数为570-710倍。根据SDS-聚丙烯酰胺平板凝胶电泳和免疫化学标准判断,这些制剂不含污染性血清蛋白。通过将新鲜采集的NHS加10 mM EDTA通过单特异性抗C5琼脂糖4B柱后获得的未吸附蛋白组分制备出C5缺失试剂(C5D)。用Ca2+、Mg2+和C1q重构C5D后,该试剂用于检测和定量C5溶血活性。纯化的C5制剂每毫克蛋白含有1.5-2.5×10¹²个有效分子,NHS每毫升含有0.5-2.0×10¹¹个有效分子。